Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2022-05-12 Capital/Financing Update
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Augmentation de moyens au contrat de liquidité avec Natixis ODDO BHF
Capital/Financing Update Classification · 95% confidence The document announces an amendment (avenant n°2) to an existing liquidity contract with Natixis ODDO BHF, specifically increasing the financial resources allocated to this contract by 5,000,000 €. This action relates directly to the company's capital management, financing arrangements, and stock market operations, as it concerns market making/liquidity provision for its shares. This fits best under 'Capital/Financing Update' (CAP), as it is a change to a financing/market support agreement, rather than a general regulatory filing (RNS) or a transaction in own shares (POS), which usually refers to buybacks/issuance directly by the company itself.
2022-05-12 French
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
Regulatory Filings Classification · 100% confidence The document is a press release dated May 4, 2022, announcing that bioMérieux received FDA *De Novo* authorization for its BIOFIRE® Joint Infection (JI) Panel. This type of announcement, detailing a specific regulatory clearance or approval for a product, is typically classified as a general regulatory announcement or a news release that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a specific announcement about a regulatory event (FDA authorization) but not a comprehensive financial report, the most appropriate category is the general Regulatory Filings (RNS) fallback, as it is a formal communication to the market about a regulatory milestone. It is not an Earnings Release (ER), Interim Report (IR), or a specific filing like DEF 14A or 10-K.
2022-05-04 English
Avril 2022 - Déclaration sur le nombre d'actions composant le capital social et le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it provides 'Informations mensuelles relatives au nombre total de droits de vote et d'actions' (Monthly information relating to the total number of voting rights and shares) as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This content, detailing the total number of shares and theoretical voting rights as of a specific date (30/04/2022), is a standard regulatory disclosure in France concerning share capital structure and voting power. This specific type of disclosure, focusing purely on the count of shares and voting rights, does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory filing related to share capital changes or structure updates. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit as it deals directly with the number of shares and voting rights, although it is a recurring monthly disclosure rather than a one-time capital event. However, since it is a mandatory regulatory filing detailing share structure, and 'RNS' is the general fallback, I must check if there is a better fit. The content is a direct report of share/voting rights data, not an announcement *about* a report. SHA covers capital changes, which includes reporting the current state of shares. If SHA is interpreted broadly to include mandatory disclosures on share count, it fits. If not, RNS is the fallback. Given the highly specific nature of the data (voting rights count), and the lack of a dedicated 'Voting Rights Disclosure' code, SHA (Share Issue/Capital Change) is the most relevant category describing the subject matter, even if it's a routine update. I will classify it as SHA due to the direct focus on the number of shares and voting rights.
2022-05-03 French
AG 2022 - Avis de mise à disposition des documents préparatoires à l'Assemblée générale mixte du 23 mai 2022
AGM Information Classification · 95% confidence The document is titled "Avis de mise à disposition des documents relatifs à l'Assemblée générale mixte du 23 mai 2022" (Notice of availability of documents relating to the Combined General Meeting of May 23, 2022). This explicitly announces the upcoming Annual General Meeting (AGM) and details where related documents can be accessed. Since the document itself is a notice about the AGM documents and not the presentation materials or voting results, it fits best under the category for AGM-related announcements. Given the options, AGM-R (AGM Information) is the most appropriate code, as it covers materials shared during the AGM, and this notice precedes it. Alternatively, RPA (Report Publication Announcement) could apply as it announces the availability of documents, but AGM-R is more specific to the event type.
2022-04-13 French
bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution
M&A Activity Classification · 98% confidence The document is a press release dated April 12th, 2022, announcing that bioMérieux has entered into an agreement to acquire Specific Diagnostics. It details the strategic rationale (fighting antimicrobial resistance), the technology involved, and the financial terms of the acquisition (acquisition price relative to market cap, expected dilution, and closing timeline). This type of announcement, detailing a significant corporate transaction (M&A), falls under the 'M&A Activity' category. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific corporate action announcement.
2022-04-12 English
bioMérieux renforce son engagement dans la lutte contre la résistance aux antibiotiques avec l'acquisition de Specific Diagnostics, une société innovante spécialisée dans les solutions d’antibiogramme
M&A Activity Classification · 98% confidence The document is a press release dated April 12, 2022, announcing that bioMérieux has entered into an agreement to acquire Specific Diagnostics. It details the strategic rationale (combating antibiotic resistance), the financial terms of the acquisition (price relative to market cap, cash/share mix, expected dilution), and the expected closing timeline (end of Q2 2022). This type of announcement, focusing on a significant corporate transaction (M&A), aligns best with the Merger & Acquisition Activity (TAR) category. It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a detailed announcement of a transaction, it is classified as TAR rather than the general fallback RNS.
2022-04-12 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.